2 results
Approved WMORecruiting
To compare the efficacy of 7.5 mg/kg of crizanlizumab versus placebo on the annualized rate of VOC leading to healthcare visit, in addition to standard of careTo compare the efficacy of 5.0 mg/kg of crizanlizumab versus placebo on the annualized…
Approved WMORecruiting
This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. The study comprises two subparts, 1 (PK/PD) and 2 (proof of concept); both subparts will be conducted in parallel. To…